# Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease

> **NCT02055079** · PHASE3 · UNKNOWN · sponsor: **Medical University of Vienna** · enrollment: 68 (estimated)

## Conditions studied

- Polycystic Kidney, Type 1 Autosomal Dominant Disease
- Polycystic Kidney, Type 2 Autosomal Dominant Disease

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02055079
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-04
- **Primary completion:** 2019-04
- **Final completion:** 2019-12
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02055079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02055079, "Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02055079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*